A Study Comparing Pembrolizumab and Sacituzumab Govitecan to Standard of Care for Urothelial Cancer
Phase 3
320
about 3.1 years
18+
114 sites in CA, FL, GA +19
What this study is about
Researchers are testing whether pembrolizumab and sacituzumab govitecan, a combination treatment, are more effective than standard chemotherapy in treating urothelial cancer that has spread or cannot be removed surgically. The trial will compare the effectiveness of this new treatment to usual care with drugs like cisplatin, carboplatin, gemcitabine, docetaxel, and paclitaxel.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Questionnaire Administration
- 2.Receive Pembrolizumab
- 3.Receive Sacituzumab Govitecan
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
carboplatin, cisplatin (Platinum chemotherapy; crosslinks DNA to stop replication), docetaxel, gemcitabine, paclitaxel (Taxane chemotherapy; stabilizes microtubules), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer), sacituzumab govitecan
injection, intravenous, infusion, injection (Injection)
Primary: Overall survival (OS)
Secondary: Clinical benefit rate (CBR), Duration of response (DOR), Incidence of adverse events (AEs), Overall response rate (ORR), Progression-free survival (PFS)
diagnostic, imaging
Oncology